A Real-World Exploratory Study on the Sleep-Improving Efficacy of Dong'e Brand Ejiao Yuanjiang
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Studietype
Studietype
Inschrijving (Werkelijk)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Zhejiang
-
Wenzhou, Zhejiang, China, 325000
- The 2nd Second Affiliated Hospital of WMU Phase I Clinical Trial Unit /Center Of Bioequivalence Study
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Males and non-pregnant, non-lactating females aged 25-55 years (inclusive; subjects exceeding 55 years of age during the trial will not be excluded);
- Body weight ≥50 kg for males and ≥45 kg for females, with a Body Mass Index (BMI) ranging from 18.5 to 27.9 kg/m² (inclusive of boundary values);
- Subjects in good general health, with no history of cardiac, hepatic, renal, gastrointestinal, neurological, psychiatric, or metabolic diseases, or any other conditions that, in the investigator's judgment, may affect the study;
- Signed the informed consent form (ICF) prior to the trial, demonstrating a full understanding of the study content, procedures, and potential adverse reactions, and capable of communicating effectively with the investigators;
- A score of ≥23 on the Self-Rating Scale of Sleep (SRSS) or ≥10 on the Pittsburgh Sleep Quality Index (PSQI);
- Self-reported sleep problems, such as difficulty falling asleep or frequent awakenings during sleep;
- Self-reported post-sleep fatigue or lethargy (e.g., feeling physically tired or mentally sluggish upon waking).
Exclusion Criteria:
- Significant abnormalities in laboratory tests (blood routine, liver and kidney function) that, in the investigator's opinion, render the subject unsuitable for participation in the trial;
- History of esophageal reflux, gastric bleeding, or peptic ulcer disease within 180 days prior to the trial; experiencing heartburn more than once a week; or having undergone any surgical procedure (e.g., cholecystectomy) that may affect the absorption of the study product;
- History of specific allergies (such as asthma, urticaria, eczema, etc.), allergic constitution (e.g., allergy to two or more drugs, foods, or pollens), or known hypersensitivity to any component of the study product;
- History of long-term and heavy alcohol consumption, or alcohol consumption habits that, in the investigator's judgment, may affect trial evaluation or subject safety;
- Pregnant, lactating, or planning to become pregnant;
- Consumption of sleep aids or neurological regulatory foods and drugs within 90 days prior to the trial;
- Presence of chronic diseases such as hypertension, hyperlipidemia, or hyperglycemia;
- History of congenital porphyria metabolism disorders (e.g., acute intermittent porphyria);
- Smoking more than 3 cigarettes per day; or alcohol consumption of ≥3 standard drinks/day for males and ≥2 standard drinks/day for females;
- A previous clinical diagnosis of severe sleep disorders or mental debility based on the International Classification of Sleep Disorders, Third Edition (ICSD-3), the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and the Chinese Guidelines for the Diagnosis and Treatment of Insomnia in Adults; or a Self-Rating Scale of Sleep (SRSS) score ≥40;
- Any other condition that, in the investigator's opinion, makes the subject unsuitable for participation in this trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Placebo-vergelijker: controlegroep
placebo
|
Placebo
|
|
Experimenteel: treatment group
Dong'e Brand Ejiao Yuanjiang
|
Dong'e Brand Ejiao Yuanjiang
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Score of Self-Rating Scale of Sleep
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Pittsburgh Sleep Quality Index
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Number of awakenings
Tijdsspanne: record everyday from the one day after enrollment to the 60th day
|
Number of awakenings is recorded from the data of Smart Band
|
record everyday from the one day after enrollment to the 60th day
|
|
Percentage of light sleep
Tijdsspanne: record everyday from the one day after enrollment to the 60th day
|
Percentage of light sleep is recorded from the data of Smart Band
|
record everyday from the one day after enrollment to the 60th day
|
|
Total Sleep Time
Tijdsspanne: record everyday from the one day after enrollment to the 60th day
|
Total Sleep Time is recorded from the data of Smart Band
|
record everyday from the one day after enrollment to the 60th day
|
|
Percentage of deep sleep
Tijdsspanne: record everyday from the one day after enrollment to the 60th day
|
Percentage of deep sleep is recorded from the data of Smart Band
|
record everyday from the one day after enrollment to the 60th day
|
|
Percentage of REM sleep
Tijdsspanne: record everyday from the one day after enrollment to the 60th day
|
Percentage of REM sleep is recorded from the data of Smart Band
|
record everyday from the one day after enrollment to the 60th day
|
|
Deep sleep continuity
Tijdsspanne: record everyday from the one day after enrollment to the 60th day
|
Deep sleep continuity is recorded from the data of Smart Band
|
record everyday from the one day after enrollment to the 60th day
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Insomnia Severity Index(ISI)
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Sleep Disorders Rating Scale(SDRS)
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Fatigue Scale-14
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Serum γ-aminobutyric acid
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
Serum γ-aminobutyric acid
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
Melatonin
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Cortisol
Tijdsspanne: At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
At baseline (screening/enrollment), and at 30 and 60 days after enrollment
|
|
|
Score of product usage experiences
Tijdsspanne: record weekly over the past 7 days
|
a questionnaire about product experiences, max score is 50, min score is 0
|
record weekly over the past 7 days
|
Andere uitkomstmaten
Andere uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
adverse event
Tijdsspanne: through study completion, an average of 2 months
|
through study completion, an average of 2 months
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Onderzoekers
Onderzoekers
- Hoofdonderzoeker: Ting Li, Second Affiliated Hospital of Wenzhou Medical University
Publicaties en nuttige links
Algemene publicaties
- Li S, Li Y, Xue C, Zhang Y, Tong T, Ouyang Z, Liu D, Cai J, Sun H. Progress in Research on the Mechanism of GABA in Improving Sleep. Foods. 2025 Nov 11;14(22):3856. doi: 10.3390/foods14223856.
- Khalid S, Bashir S, Mehboob R, Anwar T, Ali M, Hashim M, Waseem H, Basharat S. Effects of magnesium and potassium supplementation on insomnia and sleep hormones in patients with diabetes mellitus. Front Endocrinol (Lausanne). 2024 Oct 29;15:1370733. doi: 10.3389/fendo.2024.1370733. eCollection 2024.
- 1)参考《保健食品功能检验与评价方法(2023)》
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Werkelijk)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
Andere studie-ID-nummers
- SAHoWMU-CR2026-03-111
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .